Broadcom Stabilises but the Price-to-Target Gap Stays Extreme

AVGO has clawed back some ground after last week's brutal selloff, but the recovery is modest and the central tension in this story has not changed: the stock is at $334.37 while the Street's mean price target is $527.

The previous note documented a 9.1% weekly decline to $328.75, the lowest close in months. This week the stock has recovered slightly, but remains down 6.4% on the week and 6.5% on the month. The gap between price and analyst consensus has barely moved. At $334.37, the mean target of $527 implies roughly 58% upside, almost exactly as extreme as the 60% implied last week. The market is still voting in one direction while analysts point firmly in the other. Peers confirm this is not an isolated recovery: ARM fell 13.4% on the week, AOSL dropped 10.9%, and CEVA lost 6.4%, so the semiconductor sector remains under pressure even as AVGO found a temporary floor.

Options positioning reflects the cautious tone, though not at an extreme. The put/call ratio is running just above its recent average at 1.02, compared to a 20-day mean of 1.00, with a z-score of around 1.1. That places it above the midpoint but well below the 52-week high of 1.23. Investors are marginally more defensive than usual, but not panicking. The borrow market tells a similarly relaxed story. Short interest has crept up 5.5% over the past week to 1.2% of free float, continuing a gradual drift higher that has now extended to a 12.6% rise over the past month. At those levels, short interest remains structurally low. The lending pool is effectively unlimited: borrow availability shows no constraint whatsoever, and cost to borrow has collapsed to 0.18%, down sharply from 0.67% a week ago. Whoever is building the short book is doing so cheaply and without friction.

The Street's bull and bear cases have been well-rehearsed since the September 3 earnings print, and the analyst moves that followed remain the freshest data on record, now roughly six weeks old. Bulls point to 85% revenue growth, AI semiconductor revenue of $20.8 billion in the most recent quarter, and management guidance of $115 billion in AI semiconductor revenue for FY27 and $230 billion in FY28. Custom XPU shipments are up 3.5x, and the networking business continues to compound. Bears argue the mix shift toward custom silicon is compressing gross margins toward 72%, that non-AI semiconductor revenue and AI networking came in below expectations, and that multi-sourcing risk or GPU substitution could undercut future growth. The valuation picture has compressed with the stock. The PE multiple is now 18.7x, down 2.3 points over the past month. Price-to-book is at 9.6x, also falling. Neither level screams distress for a company growing this fast, but both are moving in the wrong direction.

One secondary datapoint worth noting: Broadcom's buyback activity tells its own story. ORTEX Alt Data shows buyback spend in Q2 2026 fell 76% compared to Q2 last year, to $600 million, with shares repurchased down 88%. That reduction in capital return activity, at a moment when the stock has sold off sharply, is the kind of detail that bulls will want management to address. Separately, the most recent insider activity on record involves Director Henry Samueli selling shares on September 23 under a pre-arranged 10b5-1 plan, totalling roughly $90 million across multiple tranches. Planned sales under 10b5-1 schedules carry limited informational weight, but the aggregate is notable in context.

The next scheduled earnings event is December 10. With 50 days to run, the question for the next several weeks is whether the stock can narrow the gap to analyst targets on its own, or whether it needs the fundamental update to do the heavy lifting.